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See related editorial on page
455.doi:10.1016/j.jtcvs.2006.02.062bjective: The study objective was to evaluate in a prospective, randomized,
ulticenter trial the safety and efficacy of mitral valve surgery with and without the
orCap cardiac support device (Acorn Cardiovascular, St Paul, Minn) in patients
ith New York Heart Association Class II to IV heart failure.
ackground: Although mitral valve surgery has been performed successfully in
atients with heart failure, the safety and long-term efficacy have not been estab-
ished in a multicenter prospective trial. Cardiac support devices that reduce ven-
ricular wall stress and promote beneficial reverse remodeling have been proposed
s a new treatment option as a stand-alone procedure and as an adjunct to mitral
alve surgery.
ethods: A subgroup of 193 patients were enrolled in the mitral valve repair or
eplacement stratum of the Acorn Clinical Trial; 102 patients were randomized to
he mitral valve surgery alone group (control) and 91 patients were randomized to
itral valve surgery with implantation of the CorCap cardiac support device.
atients were followed for a median duration of 22.9 months.
esults: For the entire mitral valve surgery group, the 30-day operative mortality
ate was only 1.6% at 30 days. Mitral surgery was associated with progressive
eductions in left ventricle end-diastolic volume, left ventricle end-systolic volume,
nd left ventricular mass, and increases in left ventricle ejection fraction and
phericity index, all consistent with reverse remodeling. Recurrence of clinically
ignificant mitral regurgitation was uncommon. Quality of life, exercise perfor-
ance, and New York Heart Association functional class were all improved.
inally, the addition of the CorCap cardiac support device led to greater decreases
n left ventricular end-diastolic volume and left ventricular end-systolic volume, a
ore elliptical shape, and a trend for a reduction in major cardiac procedures and
mprovement in quality of life compared with mitral surgery alone.
onclusions: These findings suggest that there is clear benefit to the surgical
limination of mitral regurgitation and that there is additional benefit with the
orCap cardiac support device. Given the improvement in left ventricle structure
nd function, along with a low mortality rate, physicians should strongly consider
ffering mitral valve surgery in combination with the CorCap cardiac support device
o patients with heart failure who are on an optimal medical regimen.
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A
CDitral regurgitation (MR) is commonly observed in
patients with heart failure (HF) and is associated
with a poor prognosis.1-4 Mitral valve repair o
eplacement to restore valve competency is a well-estab-
ished procedure when there are symptoms of HF and pri-
ary disease of the valve leaflets (eg, degenerative valve
isease).1,3 Recent interest has focused on “functional”
econdary MR in which the valve leaflets are anatomically
ormal but do not fully coapt because of annular dilation
nd restricted leaflet motion secondary to increased left
entricular (LV) size and sphericity.5,6 Valve surgery in th
ituation is controversial because MR is the consequence
nd not the cause of LV dysfunction, the prognosis is more
elated to the underlying cardiomyopathic process, and the
limination of a low-pressure run-off might worsen the over-
oad on the left ventricle. Nonetheless, MV repair with a ring
o reduce annular size has been associated with improved
V structure and patient symptoms.7-10 However, the peri-
perative mortality risk, long-term survival, and actual clin-
cal benefit are unknown.
We previously reported the results of the Acorn Clinical
rial demonstrating the safety and efficacy of the CorCap
ardiac support device (CSD) (Acorn Cardiovascular, St
aul, Minn) in patients with HF.11 This multicenter, pro-
pective, randomized trial enrolled 300 patients with HF
nto 1 of 2 strata, including the mitral surgery stratum (n 
93 patients) and the no MV surgery stratum (n  107
atients). The primary objective of the mitral surgery stra-
um was to determine whether the addition of the CorCap
SD added incremental value to MV surgery. However, it
lso provided an opportunity to assess the long-term effects
f MV surgery in a large cohort of patients with HF fol-
owed in a prospective multicenter trial with the use of an
chocardiographic core laboratory.
ethods
he Acorn Trial was a prospective, randomized, controlled eval-
ation of the CorCap CSD in patients with dilated cardiomyopa-
hy, as previously described.12 Patients were enrolled into 1 o
trata depending on whether they required MV surgery because of
ignificant MR, based on the assessment by site clinicians. Patients
ho had clinically significant MR and an indication for MV
urgery were enrolled in the MV surgery stratum (n  193 pa-
ients) and then randomized to treatment (MV surgery plus CSD,
 91) or control (MV surgery alone, n  102). Patients without
clinical indication for MV surgery were enrolled in the no MV
urgery stratum (n  107 patients), but they are not discussed in
his report.
Patients were eligible for the Acorn Trial if they had New York
eart Association (NYHA) Class III and IV HF of ischemic or
on-ischemic cause and were between the ages of 18 and 80 years.
ll patients had an LV ejection fraction of 35% or less, LV dilation
defined as an LV end-diastolic dimension 60 mm or an LV
nd-diastolic dimension index 30 mm/m2), a 6-minute walk test
6MWT) less than 450 m, and acceptable laboratory and pulmo- v
The Journal of Thoracicary function test results. Most patients received an optimal med-
cation regimen that included a diuretic (at least “as needed”), an
ngiotensin-converting enzyme (ACE) inhibitor (or angiotensin
eceptor blocker if ACE intolerant), and a beta-blocker (for at least
months). There were 2 inclusion criteria specific to the MV
urgery stratum. First, the doses of background medication did not
ave to be stable for 1 month because of concerns regarding
dditional safety risks to delaying surgery for significant MR.
econd, patients could also be enrolled with NYHA Class II
ymptoms and an ejection fraction of up to 45%. Specific exclu-
ion criteria were summarized previously.12
Baseline testing included blood tests, echocardiography, qual-
ty of life evaluation with the Minnesota Living with Heart Failure
uestionnaire (MLHF) and the Short-Form 36 (SF-36) Question-
aire, 6MWT, and an exercise test to measure peak oxygen con-
umption (peak VO2). Randomization to treatment or control
roups was stratified by site and stratum and based on random
ermuted blocks.
MV surgery was performed using standard operative tech-
iques including cardiopulmonary bypass and undersized MV
nnuloplasty ring placement or valve replacement. CorCap CSD
mplant techniques were summarized previously.13 Patients were
een at 3 months, 6 months, and then every 6 months. Blood tests,
chocardiography, quality of life surveys, and 6MWT were com-
leted at all visits. Peak VO2 was measured at 6 and 12 months.
ata on events (ie, deaths, hospitalizations, adverse events, and
ajor cardiac procedures [MCPs]) were collected until the com-
on closing date, which was specified to be after the last enrolled
atient had been followed for 1 year. All echocardiographic data
LV size, function, shape, mass, and MR severity) were obtained
rom readings by the Core Laboratory at the Mayo Clinic, which
ad no knowledge of clinical or randomization data.
End points included all-cause mortality and change in NYHA
unctional class, quality of life, 6MWT and peak VO2, LV ejection
raction, LV volumes, MR, and LV sphericity index. Patients were
lso followed for the need for additional MCPs (transplant, left
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CSD  cardiac support device
HF  heart failure
LV  left ventricular
LVEDV left ventricular end-diastolic volume
LVEF  left ventricular ejection fraction
LVESV  left ventricular end-systolic volume
MCP major cardiac procedure
MLHF Minnesota Living with Heart Failure
Questionnaire
MR mitral regurgitation
MV mitral valve
NYHA  New York Heart Association
OR  odds ratio
SF-36  Short-Form 36
6MWT  6-minute walk testentricular assist device, biventricular pacemakers, repeat MV
and Cardiovascular Surgery ● Volume 132, Number 3 569
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A
CDurgery, tricuspid valve surgery, and coronary artery bypass graft-
ng), which would indicate worsening of HF. Biventricular pace-
akers and repeat MV surgery were adjudicated by an indepen-
ent Clinical Events Review Committee, and only those events
onsidered to be associated with worsening HF were counted
oward the end point. Safety end points included the rate of deaths
nd serious adverse events overall. All efficacy and safety end
oints were analyzed according to the intention-to-treat principle.
umulative survival curves for all events were constructed accord-
ng to the Kaplan-Meier method, and differences were tested by
he Cox-risk statistic. Comparisons of changes from baseline to
ollow-up were evaluated with t tests, chi-square statistics, or
ongitudinal regression analysis as appropriate.
esults
 total of 193 patients were enrolled in this study (
1). The mean age was 53.4  12.6 years. The mean L
olume was 270.1 100.3 mL, LV end-diastolic dimension
as 69.7  8.8 mm (site assessment), and LV ejection
raction was 23.9%  8.9% (site assessment). Patients had
imited functional capacity with a mean 6MWT of 344.3 
0.4 m, a peak VO2 of 14.1  4.3 mL/kg/min, an MLHF
core of 58.8  23.9 units, and a physical functioning score
SF-36) of 37.1  22.9 units. This trial was different from
ther HF trials because a majority of the patients in this trial
ere female (54.4%), with a large percentage of non-white
inorities (39.9%). Most patients were in NYHA Class III
71.5%), with 23.3% in Class II and 5.2% in Class IV. The
ause of HF was idiopathic in most patients; only 12 patients
6.2%) had ischemic heart disease. Background medical ther-
py included 97.4% receiving ACE inhibitors or angiotensin
eceptor blockers and 80.3% receiving beta-blockers.
Table 1 summarizes the echo core laboratory determ
ions of MR severity. There were 44 patients (23.3%) with
 MR, 49 patients (25.9%) with 3 MR, and 62 patients
32.8%) with 4 MR. Fourteen patients (7.4%) had a core
aboratory determination of 0 MR (none or trivial), and 20
atients (10.6%) had a core laboratory determination of 1
R. It should be noted that the echo core laboratory read-
ABLE 1. Mitral regurgitation severity mitral valve replace
R severity
Baseline
(189 patients)
6 m
(154 pa
No. % No.
14 7.4 94
 20 10.6 34
 44 23.3 13
 49 25.9 10
 62 32.8 3
ean score 2.66 0.6
vs baseline — .0
R, Mitral regurgitation.ngs were used solely for tracking end points in the trial and f
70 The Journal of Thoracic and Cardiovascular Surgery ● Septee
ere not considered in the clinical decisions to perform
itral surgery. Most patients had multiple studies assessing
R severity, including contrast ventriculograms and trans-
sophageal echocardiography, all of which were factored in
he indication of MV surgery.
Nine of the 193 patients did not undergo MV surgery (5
atients refused, 1 patient died before surgery, and it was
urgically decided for 3 patients). Most patients (n  155
atients; 84.2%) received a mitral annuloplasty ring, but 29
atients (15.8%) underwent MV replacement. The baseline
haracteristics of the patients who underwent repair and
eplacement were similar. The only statistical difference
as that the MV replacement group included more patients
ho had a history of cardiac surgery (3 vs 1, P  .002). In
eneral, surgeons chose replacement if there were anatomic
bnormalities (eg, rheumatic disease) or when it was be-
ieved that repair would not yield a satisfactory result. The
eplacement group included 4 patients who were converted
rom repair to replacement at the time of the original sur-
ery because transesophageal echocardiography monitoring
ndicated that the initial mitral ring did not provide a satis-
actory result (eg, eccentric MR and persistent billowing of
eaflets). During MV replacement surgery, most patients
ad preservation of both anterior and posterior chordal
tructures. For MV repair, a variety of different ring types
ere used (Table E2). Information on the ring size us
he MV repair group was available in 86% of cases. A ring
ize of 26 or smaller was used in 59% of cases. The
emaining ring sizes used were 27 (6%), 28 (24.6%), 29
3.7%), 30 (3.0%), 31 (0.8%), and 32 (3.0%). Most of the
ings were complete (65%) compared with partial (35%).
Figure 1 summarizes the Kaplan-Meier survival cu
or the overall group. At 30 days, there were 3 deaths for an
verall operative mortality of 1.6%. At 12 months, the
umulative survival was 86.5%. At 24 months, the cumu-
ative survival was 85.2%.
Figure 2 summarizes the longitudinal regression analy
t stratum (core laboratory)
)
12 mo
(145 patients)
18 mo
(95 patients)
% No. % No. %
61.0 81 55.9 56 58.9
22.1 40 27.6 28 29.5
8.4 16 11.0 7 7.4
6.5 6 4.1 2 2.1
1.9 2 1.4 2 2.1
0.67 0.59
.0001 .0001men
o
tients
7
001or the change in left ventricular end-diastolic volume
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A
CDLVEDV) (Figure 2, A) and left ventricular end-systol
olume (LVESV) (Figure 2, B) from baseline to 24 mont
here was a progressive decrease in both LVEDV and
VESV that was highly significant at all time points. 
re 3 summarizes the changes in left ventricular ejec
raction (LVEF). There were small and nonsignificant
hanges in ejection fraction at 3, 6, and 12 months. At 18
igure 1. Kaplan-Meier survival curve for the entire group of 193
atients in the MV surgery stratum. See text for discussion.The Journal of Thoracic-
nd 24 months, ejection fraction increased by 4.6 (P .003)
nd 4.1 (P  .03), respectively.
Sphericity index increased by 0.037 at 3 months (P 
02), 0.092 at 6 months (P  .0001), 0.088 at 12 months
P  .0001), 0.116 at 18 months (P  .0001), and 0.197 at
4 months (P  .0001), all consistent with a more ellipsoi-
al shape. LV mass index also decreased, consistent with a
eneficial effect on remodeling. From a baseline of 306.7
/m2, LV mass index decreased by 38.0 at 3 months (P 
0001), 48.1 at 6 months (P  .0001), 47.4 at 12 months
P  .0001), 47.4 at 18 months (P  .0004), and 72.81 at
4 months (P  .0001).
Overall, there was a dramatic reduction in the severity of
R (Table 1). The mean MR severity at baseline of
as reduced to 0.67 at 6 months (P  .0001), 0.67 at 12
onths (P  .0001), and 0.59 at 18 months (P  .0001).
epeat MV surgery was performed in only 4 patients during
ollow-up.
Figure E1 summarizes the changes in MLHF. Ove
cores decreased significantly at 3, 6, 12, 18, and 24 months
all P  .0001), consistent with an improvement in quality
f life. Similarly, improvements were observed with the
Figure 2. A, Reduction in LVEDV for the entire
group of 193 patients in the MV surgery stratum.
There was a progressive and significant reduc-
tion in LVEDV at 3, 6, 12, and 18 months, consis-
tent with reverse remodeling. The number of
patients studied at each time point is indicated.
B, Reduction in LVESV for the entire group of 193
patients in the MV surgery stratum. Similar to the
changes in LVEDV, there was a progressive and
significant decrease in LVESV at 3, 6, 12, and 18
months. LV, Left ventricular.and Cardiovascular Surgery ● Volume 132, Number 3 571
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A
CDF-36, a general quality of life instrument, with significant
mprovements in the general health domain at 3, 6, and 12
onths. NYHA functional class also improved. The base-
ine NYHA class of 2.82 was reduced to 2.36 at 3 months
P  .0001), 2.34 at 6 months (P  .0001), 2.31 at 12
onths (P  .0001), 2.20 at 18 months (P  .0001), and
.25 at 24 months (P  .0001). Exercise performance as
easured by the 6MWT also increased significantly for the
verall group. There were significant increases of 21.8 
.1 m at 3 months (P  .003), 26.4  7.3 m at 6 months
P  .0004), 32.2  7.4 m at 12 months (P  .0001), and
0.4  9.9 m at 18 months (P  .0001). There were no
ignificant changes in peak VO2 for the entire group at 6
onths (mean change 0.11 mL/kg/min; P  .76) or 12
onths (mean change 0.07 mL/kg/min; P  .85).
The 84% of patients undergoing MV repair were com-
ared with the 16% of patients undergoing MV replace-
ent. There were no differences in survival between the
epair and replacement groups. At 30 days, there were 3
eaths in the repair group (155 patients) and no deaths in the
eplacement group (29 patients).
The MV surgery/CSD (treatment) group and the MV
urgery alone (control) group were compared to assess the
dditive effect of the CorCap CSD to MR surgery. There
as no significant difference in survival between the treat-
ent and control groups. At 30 days, there were 2 deaths in
he treatment group (2.2%) and 1 death in the control group
1.0%). At 12 and 24 months, the cumulative mortality rate
as 12.1% and 13.5%, respectively, in the treatment group
ompared with 14.8% and 15.9%, respectively, in the con-
rol group.
The Kaplan-Meier freedom from MCP curve (Figure 
hows that the treatment group tended to have fewer MCPs
han the control group (P .11). Compared with the control
roup, the treatment group had fewer cardiac transplants (6
s 12), fewer left ventricular assist devices (3 vs 7), fewer
epeat MV operations (1 vs 3), fewer biventricular pace-
akers (6 vs 8), and fewer tricuspid valve surgeries (0 vs 2), w
72 The Journal of Thoracic and Cardiovascular Surgery ● Septeut none of these differences were statistically significant.
igure E3shows the freedom from the combined end p
f death or MCP, with a trend for a reduction in the
reatment group (P  .09).
The control group demonstrated a progressive decrease
n LVEDV (Figure 4, A), which likely reflects the benefic
ffects of MV surgery. The treatment group demonstrated a
ignificantly greater decrease in LVEDV (average differ-
nce 15.5 mL; P .043) indicating that the CorCap CSD
ad an additive effect to the MV surgery. Similar changes
ere observed with LVESV (Figure 4, B). The averag
eduction in LVESV in the treatment group was signifi-
antly greater than in the control group by 14.6 mL (P 
044). The treatment group had a greater increase of 1.87
jection fraction units compared with the control group, but
his difference was not significant (P  .23).
Sphericity index increased more in the treatment group
0.071 units, P  .003). LV mass index tended to decrease
ore in the treatment group by an average reduction of 6.4
/m2, but this difference was not significant (P  .23). MR
everity was similar between the 2 groups. In the treatment
roup at 6 months, 60.3% had no MR, 28.2% had 1 MR,
nd 2.6% and 2 MR. In the control group, 61.8% had no
R, 15.8% had 1MR, and 14.5% had 2MR. There was
o significant difference in MR severity between the groups
t 6, 12, or 18 months.
MLHF scores decreased in both groups consistent with
n improvement in quality of life specific to HF. The
reatment group demonstrated a greater decrease in MLHF
4.22 units) when compared with the control group (P 
13). Similar patterns were observed in the SF-36. Com-
ared with the control group, the treatment group demon-
trated a greater improvement in the general health domain
10.39 units, P  .0001) and the physical function domain
5.16 units, P  .078).
Comparison of 6MWT and peak VO2 responses between
he treatment and control groups was difficult because data
Figure 3. Change in LV ejection fraction for the
entire group of 193 patients in the MV surgery
stratum. There were insignificant changes in
LVEF at 3, 6, and 12 months. The increase in
ejection fraction at 18 months was significant at
P  .003. LV, Left ventricular.ere missing for cause. Many patients could not perform the
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A
CDollow-up exercise test typically because of clinical deteriora-
ions. Moreover, patients who missed tests had significantly
ore advanced HF than patients who completed the labo-
atory tests. Furthermore, patients in the control group were
issing tests. Therefore, to avoid the bias produced by
issing tests, we performed rank-order analysis. For the
MWT, patients in the treatment group tended to have a
etter category than the control group at 6 months (odds
atio [OR]  1.40; P  .19) and 12 months (OR  1.37;
 .22), but neither change was significant. Similarly, for
eak VO2, patients in the treatment group tended to have a
etter category at 6 months (OR  1.36 ; P  .27) and 12
onths (OR  1.47; P  .16), but neither change wasignificant. c
The Journal of ThoracicTable 2 summarizes the number of patients experienc
serious adverse event at any time during follow-up. Over-
ll, 82.4% of the treatment group and 79.4% of the control
roup had a serious adverse event. The number of patients
nd types of adverse events were not statistically different
etween the groups. There were no clinical cases of con-
triction in any patient.
iscussion
he Acorn Clinical Trial represented a unique opportunity
o prospectively assess the safety and efficacy of MV sur-
ery in patients with HF. Twenty-nine centers participated,
single echocardiography core laboratory made all of the
Figure 4. A, Reduction in LVEDV (longitudinal
regression analysis) for the control group (no
CSD) and treatment group (with CSD). The con-
trol group demonstrated a reduction in LVEDV
consistent with a reverse remodeling effect from
the mitral surgery alone. The treatment group
had a statistically significantly greater reduction
in LVEDV (P  .043), indicating that the CorCap
CSD had an additive effect to MV surgery. B,
Reduction in LVESV (longitudinal regression
analysis) for the control group (no CSD) and
treatment group (with CSD). Findings are similar
to the changes in LVEDV. See text for discussion.
LVEDV, left ventricular end-diastolic volume;
LVESV, left ventricular end-systolic volume.ardiac structural measurements, and all patients were
and Cardiovascular Surgery ● Volume 132, Number 3 573
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CDreated with intensive background medical therapy. In pa-
ients with primarily non-ischemic HF and severe LV dys-
unction, the present trial demonstrated that MV surgery
as safe, had a low operative mortality rate, and was
ssociated with a remarkable reversal of LV remodeling, as
anifested by a decrease in LVEDV and LVESV, an im-
rovement in LVEF and sphericity index, and a reduction in
V mass. MR was effectively reduced and maintained for at
east 18 months of follow-up. Patient quality of life was
mproved, as demonstrated by significant improvements in
different quality of life measures and submaximal exer-
ise. Finally, the concomitant implant of the CorCap CSD
ad an additive effect, with a significantly greater reduction
n LV size, a more elliptical shape, and a trend for a
eduction in MCPs and improvement in quality of life.
LV remodeling is characterized by progressive LV dila-
ation and a change to a more spherical shape. In response
o infarction or volume overload, the ventricle dilates, re-
ulting in an increased radius of curvature and increased LV
all stress, both of which propagate progressive LV remod-
ling.14,15 However, there are no therapies specific for 
reatment of progressive LV dilation, which is one of the
trongest predictors of mortality.16,17
Progressive LV remodeling can also result in functional
R because of annular dilatation, papillary muscle dis-
lacement, and chordal tethering. This functional MR leads
o increased preload, increased wall tension, and increased
V work load, all of which contribute in a positive feedback
oop to progressive HF. The presence of MR is an indepen-
ent risk factor of poor outcome.2-4
Although traditional teaching is that surgical correction
f MR may have a prohibitive operative mortality,18,19 this
iew has been challenged by Bolling and others.7-10,14,20-22
ABLE 2. Patients experiencing serious adverse events by
Treatment (n  91)
No. of patients Percen
llergic response 3
rrhythmia 33 3
leeding 6
emodynamic compromise 52 5
epatic compromise 2
nfection/pneumonia 33 3
yocardial infarction 0
eurologic deficit/stroke 14 1
eripheral thrombus/embolism 2
ulmonary compromise 22 2
ulmonary embolism 0
enal compromise 8
ther 36 3
ny of the above SAE 75 8
AE, Serious adverse event. *Obtained from Cochran-Mantel-Haenszel tehe alternate hypothesis is that reconstruction of the MV a
74 The Journal of Thoracic and Cardiovascular Surgery ● Septennulus with an undersized ring, by restoring valvular com-
etency, would alleviate excessive ventricular workload.
ibayan and colleagues14 reported in an ischemic she
odel of MR that reduction of the annulus by a small ring
educes the radius of curvature of the LV at the base,
quatorial, and apical levels. This decrease in the radius of
urvature supports the concept that a small ring can restore
more elliptical shape.
In a recent retrospective analysis, Wu and colleagu23
xamined 126 patients treated with MV repair and a control
roup of 293 patients treated medically and matched by
ropensity methods. In this nonrandomized series, the out-
omes indicated that there was no mortality benefit of MV
epair. This study did not report changes in LV size or
unction or patient symptoms.
In the present trial, the overall 30-day mortality was 1.6%.
his is one of the lowest mortality rates of any series9,20-22 and
s especially noteworthy because it represents the outcomes of
ultiple centers. Repair of functional MR with a small annu-
oplasty ring remained stable over time with more than 80% of
atients with 0/1MR at 6 to 18 months. The reversal of LV
emodeling, manifested by a decrease in LVEDV and LVESV,
n improvement in LVEF and sphericity index, a reduction in
V mass, and an improvement in quality of life and exercise,
ll suggest that MV surgery in patients with non-ischemic HF
s a safe and effective procedure. Because only 6% of patients
ad ischemic heart disease in this trial, we cannot make state-
ents regarding patients with ischemic MR. Further, a trial in
hich patients are randomized to MV surgery or medical
herapy will be necessary to provide definitive data on the “MR
ypothesis.”24
Passive containment by the CorCap CSD was first re-
orted in an animal model of chronic dilated cardiomyop-
tment group: Mitral valve surgery stratum
Control (n  102)
P value*of 91 No. of patients Percentage of 102
1 1.0 .22
44 43.1 .35
13 12.7 .14
47 46.1 .13
0 0.0 .14
28 27.5 .19
1 1.0 .35
7 6.9 .06
2 2.0 .92
19 18.6 .35
1 1.0 .35
6 5.9 .42
43 42.2 .68
81 79.4 .61trea
tage
3.3
6.3
6.6
7.1
2.2
6.3
0.0
5.4
2.2
4.2
0.0
8.8
9.6
2.4thy.25-27 These studies demonstrated that CSD-treated
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CDearts actually demonstrated significant decreases in vol-
me and improvement in function, all consistent with re-
erse remodeling. A reversal of remodeling on a cellular
nd molecular level was further demonstrated.25-27 More
ecently, the CSD has also been shown in an acute infarct
odel to limit infarct expansion, improve myocardial ener-
etics, and attenuate the expression of certain cellular de-
erminants of the remodeling process.28,29 The results of th
ulticenter, randomized, prospective trial of the CorCap
SD in patients with advanced HF have been report11
ore patients “improved” and fewer patients “worsened” in
he CSD group (OR of 1.73) (1.07-2.79; P .02) compared
ith the control group. The CSD group had fewer MCPs
ompared with the control group (19 vs 33; P  .01), a
reater reduction in LV end-diastolic (P  .008) and sys-
olic volumes (P  .017), a greater improvement in sphe-
icity index (P  .031), and improved quality of life. There
ere no reports of constrictive physiology in these patients.
Although not powered to be considered separately, the
VR stratum demonstrated that the addition of the CorCap
SD to standard MV surgery resulted in significant additive
enefit. There was a significantly greater reduction in LV
olumes and greater improvements in the sphericity when a
SD was added to MV surgery. In addition, there was a
rend toward fewer MCPs. The need for an additive ven-
ricular procedure such as the CSD was suggested by Hung
nd colleagues,30 who studied 30 patients with ischem
ardiomyopathy. They demonstrated that recurrent MR af-
er initial repair with ring annuloplasty paralleled increases
n LV volumes and sphericity index, suggesting that the
ffects of the annuloplasty ring can be overwhelmed by
ngoing ventricular remodeling.
onclusion
he low operative mortality, impressive 2-year survival,
nd evidence of improvement in LV function and NYHA
lass after MV surgery show a clear benefit to the surgical
limination of MR and a significant additional benefit with
he CorCap CSD. This combined surgical approach results
n additional reverse remodeling, minimizing ventricular
olumes and optimizing ventricular geometry. Given the
mprovement in left ventricle structure and function, along
ith a low mortality rate, physicians should strongly con-
ider offering mitral valve surgery in combination with the
orCap CSD to patients with HF who have been medically
ptimized yet remain symptomatic with significant MR.
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iscussion
r D. Miller (Stanford, Calif): I want to be the first to congratulate
r. Acker and his colleagues for conducting this randomized
rospective controlled trial. Few of you realize how much work
nd effort is involved in bring one of these studies to fruition. This
uccess is a testimonial to the investigators and a credit to the
ATS; it represents what we need more of at this meeting and in
ur journals. This is real science.
I have a question about your patient selection, Mike. They are
olid NYHA III, had an LV end-diastolic dimension of 7 cm, an
F of 24%, and a peak VO2 of 14. But, just how sick really were
hese individuals? Could that perhaps explain why you didn’t see
ifferences in survival? The overall survival rate in the Acorn CSD
roup at two years was 82%. Further, the BNP levels were normal
n over half of these patients, which our heart failure cardiologists
nd hard to believe. You and the Acorn investigators tell me the
NP levels were normal due to the maximal medical therapy these
atients were receiving preoperatively, but I am just not sure it was
sick enough subset of patients to demonstrate the differences you
anted to show in terms of survival and clinical benefit.
You told us that the vast majority of your patients had idio-
athic or valvular-related cardiomyopathy, not ischemic cardiomy-
pathy. I would like you to address that fact because I don’t want
he audience trying this at home in a coronary disease population
f patients with CHF. The ischemic MR patients are a totally
ifferent kettle of fish.
For those of you who are interested in this field, there was a
aper in JACC from Michigan by Aubrey Wu outlining Steve
olling’s entire 10-year experience in February that showed no
ifference in event-free survival at five years. This has thrown cold
ater on the whole concept of undersized mitral ring annuloplasty
or CHF. Our heart failure cardiologists wondered at the time why
as this well-done paper was accepted for publication, since they
ll thought they already knew a Bolling does not work? Well, the
ata you have presented today is going to open their eyes. To be
air, however, the Michigan CHF patients were probably sicker
han the Acorn patients.
What you have shown convincingly is that there is favorable
everse LV remodeling going on, not just in terms of EDV, but
lso for LV ESV. The external constraint must be inducing some
ncharacterized biological signal that over time is promoting pro-
ressive reduction in end-systolic LV volume and a more elliptical v
76 The Journal of Thoracic and Cardiovascular Surgery ● SepteV shape. You also have shown, in contrast to the AHA presen-
ation of the overall Acorn trial last November, that the effects on
V size persist over time. The effectiveness of the Acorn CSD in
our patients, which notably was additive to mitral annuloplasty or
eplacement, was still present out at 18 months. The skeptics at the
HA were saying that the Acorn trial picked an optimal 12-month
nterval to report their results, but you have now shown there is
ngoing salutary reverse remodeling. There was no difference in
urvival, but it would be very difficult to demonstrate an improve-
ent in survival given the very low mortality rate or even in major
dverse clinical events. Can you comment on the postoperative
xercise maximum VO2 data? This would reflect more directly
hether any functional cardiac benefits were achieved, which
ould explain why these patients felt better.
Dr Acker. As far as patient selection is concerned, I do believe
hese were sick patients. These are not generally Class IV patients.
hese are Class III patients of long duration of heart failure treated
emarkably well. I want to point out that the 80% of patients who
ere on both a beta blocker and ACE inhibitor is the highest rate
f use of beta blockers in any randomized trial to date, and I think
his really has a tremendous effect on BNP. It is our feeling,
specially at Penn, that BNP is not useful in a very, very well
anaged, medically optimized group of patients to judge their
rognosis. In fact, we do not use it at all when we discuss whether
omeone is a heart transplant candidate or not.
And finally, the recent Cleveland Clinic report of a very sick
roup of patients shows that 21% of that group of patients had an
bsolutely normal BNP. So I think though BNP is wonderful for
he patient with new heart failure, it is unclear what its value is
rognostically in a very well optimally managed medically treated
roup.
As far as ischemic cardiomyopathy and ischemic MR are
oncerned, you are right, this study does not address that subgroup
f patients. It would be wonderful to do a specific study for
schemic patients. My conjecture is that it still probably is a good
dea to eliminate MR if only for symptoms alone, but again, we
annot draw any conclusions on that.
The Michigan paper I think added significantly to the field. I
ant to remind everyone, it was not a randomized paper. It was a
etrospectively case-controlled paper that looked only at survival,
nd they found that mitral valve annular repair did not impact, was
ot an independent predictor of outcome survival transplant VAD.
However, they did not look at symptoms, they did not look at
V morphology or ejection fraction as we did in a multi-institu-
ional approach, and I think this does add significantly to the field.
lso, what is neat about this multi-institutional approach is that we
ll know Steve Bolling is an excellent surgeon and he can get these
atients through, but what we showed in this study is that 30
ifferent surgeons or more can do this type of operation with a
ery low mortality of 1.6%.
LV remodeling, which you talked about, we showed is pro-
ressive. It is not just the jacket being put on, being tightened
own, and of course, the LVs are smaller. In fact, what we saw, as
r. Miller pointed out, was that the LV remodeling is progressive,
ndicating that a signal is being changed, perhaps the relief of
iastolic wall stress, and this results in a progressive change in the
entricle.
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Acker et al Surgery for Acquired Cardiovascular DiseaseAnd finally, regarding exercise, the analysis for the entire
itral valve group for exercise is not completed yet, but I suspect
t will show a small but significant increase in 6-minute walk and
lso in peak VO2, though I do have to look at the final statistics to
now if that will be significant or not.
Dr Miller: May I ask one more question? It is important to the
all Street analysts in the audience, if there are any, the cardiologists,
etsy Nabel, who is here with us from NIH, and some surgeons. You
nd I both know that the mitral regurgitation probably is not the
undamental problem in these CHF patients. As Steve Bolling has told
s over and over, “this is a ventricular disease, dummy, not a valvular
isease.” In 1994, when I discussed Bolling’s first report at the
estern Thoracic Surgical Association meeting, I said I was flabber-
asted that most patients did not die immediately postoperatively.
our results in the mitral ring-only group now prove that Steve’s
oncept has merit, and can be done safely in many centers. The
enture capitalists, the big companies, and a dozen or more start-ups,
owever, mistakenly believe that the MR is the primary problem, not
he ventricle. They are working on minimizing functional MR (FMR)
nd IMR with an indirect coronary sinus “Cerclage” approach or
oing something akin to an Alfieri suture between the leaflets. Do you
hink this thrust is missing the boat? Do you think they have any
lausible hope of affecting subvalvular left ventricular geometry,The Journal of Thoracichanges that you have presented today after a small mitral ring or
itral valve replacement?
Dr Acker. You and I have similar views on this, as you know.
here are all different types of percutaneous approaches. The
ajority that deal just with the coronary sinus with the attempts of
ffecting the annulus substantially, and more importantly, the
entricle, I believe will fail. There are other noninvasive ap-
roaches that are ventricular approaches that may have benefit. But
think what it does speak to is that when one does this operation,
ne probably does need, at least in my belief, to add a ventricular
olution to a ventricular problem, such as the Acorn CorCap,
hich can be easily combined with mitral valve surgery to really
ffect the ventricular problem.
Dr G. Bolotin (Tel-Aviv, Israel). Do you have any data regard-
ng the severity of the adhesions from the Acorn device if the
atient in the future needs a heart transplant?
Dr Acker. Yes. There have been several heart transplants done
orldwide with people who have had Acorn jackets. Sometimes
he adhesions are severe, but no more severe than any difficult
edo. The adhesions are less severe than a redo LVAD/BVAD out
ix months or more. You must give yourself enough time to dissect
hrough the adhesions, and we had no deaths in the entire groupA
CDhich might then induce the favorable LV reverse remodeling and all the heart transplants were successful.
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CDppendix E1: Clinical Centers
dvocate Christ Medical Center, Oaklawn, Ill: M. Slaughter, M.
ilver, T. George, H. Lonergan-Thomas; Albert Einstein College
f Medicine, Bronx, NY: T. LeJemtel, M. Camacho, N. Cesare, P.
icilia; Baylor College of Medicine/VAMC Houston, Tex: E.
oltero, D. Mann, T. Lynch; Boston Medical Center, Boston,
ass: R. Shemin, G. Philippides, M. Cheney; Bryan LGH Heart
nstitute, Lincoln, Neb: E. Raines, S. Krueger, V. Norton; Cedars-
inai Medical Center, Los Angeles, Calif: K. Magliato, S. Khan, L.
efensor, M. De Robertis, D. Gallegos; Cleveland Clinic Foun-
ation, Cleveland, Ohio: N. Smedira, R. Starling, R. Schott, B.
us; Columbia-Presbyterian Medical Center, New York, NY: N.
dwards, D. Mancini, K. Idrissi, J. Dimitui Vallarta; Duke Uni-
ersity Medical Center, Durham, NC: C. Milano, S. Russell, S.
elsh, A. Skye, R. Larsen; Henry Ford Hospital, Detroit, Mich: R.
rewer, B. Czerska, K. Leszczynski, N. Wulbrecht; Hospital of the
niversity of Pennsylvania, Philadelphia, Pa: M. Acker, M.
essup, S. Baker, M. O’Hara; Jewish Hospital at University of
ouisville, Louisville, Ky: R. Dowling, G. Bhat, L. Muncy, K.
aley; Nebraska Heart Institute, Lincoln, Neb: D. Gangahar, K.
yala, L. Taylor; New England Medical Center at Tufts Univer-
ity, Boston, Mass: K. Khabbaz, D. DeNofrio, C. Grodman; New-
rk Beth Israel, Newark, NJ: D. Goldstein, M. Zucker, J. Casida;
schner Heart and Vascular Institute, New Orleans, La: C. Van77.e1 The Journal of Thoracic and Cardiovascular Surgery ● Seenter, Hershey, Pa: W. Pae, J. Boehmer, P. Ulsh, K. McFadden;
oyal Victoria Hospital/McGill University, Montreal, PQ, Can-
da: R. Cecere, N. Giannetti, C. Barber; St Louis University, St
ouis, Mo: A. Aharon, P. Hauptman, M. Jacob; Stanford Univer-
ity Medical Center/Kaiser Permanente, Stanford, Calif: R. Rob-
ins, M. Fowler, D. Weisshaar, A. Mullin, K. Town; University of
labama at Birmingham, Birmingham, Ala: J. Kirklin, B. Ray-
urn, K. Harper; University of Florida/Shands Hospital, Gaines-
ille, Fla: E. Staples, J. Aranda, D. Leach; University of Maryland
edical Center, Baltimore, Md: J. Gammie, S. Gottlieb, J. Mar-
hall; University of Michigan Hospital, Ann Arbor, Mich: S.
olling, K. Aaronson, M. Jessup, P. Obriot; University of Minne-
ota Medical Center, Minneapolis, Minn: S. Park, L. Miller, J.
raziano; University of Pittsburgh Medical Center, Pittsburgh, Pa:
. McCurry, S. Murali, T. Ryan, D. Zaldonis; VA Medical Center
an Diego Health Care System, San Diego, Calif: M. Madani, R.
habetai, C. Jaynes, R. Cremo, N. Gardetto; VA Medical Center
inneapolis, Minneapolis, Minn: H. Ward, I. Anand, J. Whitlock;
ashington Hospital Center, Washington, DC: M. Dullum, B.
arlos, J. Richmond, C. Bither, W. Varmer; Steering Committee:
. Mann (Principal Investigator), M. Acker, M. Jessup, H. N.
abbah, R. Starling; Data and Safety Monitoring Committee: G.
rancis (Chair), J. Neaton, D. Homans, C. O’Connor, W. Curtis.
linical Events Review Committee: S. Goldstein (Chair), F. Spi-eter, M. Mehra, B. Harris; Penn State/Milton Hershey Medical nale, J. Lindenfeld.ptember 2006
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A
CDFigure E1. Changes in quality of life as measured
by the MLHF for the entire group of 193 patients
in the MV surgery stratum. A reduction in MLHF
indicated an improvement in quality of life. There
were significant improvements in quality of life
at 3, 6, 12, and 18 months. MLHF, Minnesota
Living with Heart Failure Questionnaire.
Figure E2. Kaplan-Meier freedom from MCPs
for the entire group of 193 patients in the MVR
stratum. The control group (bold line; n  102
patients) had a greater number of MCPs than the
treatment group (regular line; n  91 patients).
MCP, Major cardiac procedure.The Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 3 577.e2
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A
CDFigure E3. Kaplan-Meier freedom from the com-
bined end point of death or MCP for the 193
patients in the MV surgery stratum. Control pa-
tients tended to have more deaths and MCPs
when compared with the treatment group (P 
.09). MCP, Major cardiac procedure.77.e3 The Journal of Thoracic and Cardiovascular Surgery ● September 2006
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A
CDABLE E1. Baseline characteristics: Mitral valve replace-
ent stratum
aseline characteristic
No. with
data
Mean or
percentage
ge (y) 193 53.4
o. of previous hospitalizations 193 1.0
ears since heart failure diagnosis 193 4.7
VEDD (mm) (site) 193 69.7
V volume (mL) core 174 270.1
VEF (%) (site) 193 23.9
-minute walk distance (m) 191 344.3
LHF score 193 58.8
hysical Function Domain, SF-36 192 37.1
eneral Health Domain, SF-36 193 36.8
eak V02 (mL/kg/min) site 172 14.4
UN (mg/dL) 193 23.4
reatinine (mg/dL) 193 1.2
odium (meq) 193 138.5
eart rate 193 77.3
BP (mm Hg) 193 70.0
BP (mm Hg) 193 111.1
ender: male 88 45.6
ender: female 105 54.4
ace: white 116 60.1
ace: black 59 30.6
ace: other 18 9.3
YHA Class II (site assessed) 45 23.3
YHA Class III (site assessed) 138 71.5
YHA Class IV (site assessed) 10 5.2
ercentage on beta-blocker 155 80.3
ercentage on ACE or ARB 188 97.4
ercentage on spironolactone 84 43.5
ause†
schemic heart disease 12 6.2
diopathic 117 60.6
alvular 33 17.1
ther 52 27.0
VEDD, Left ventricular end-diastolic diameter; LV, left ventricular; LVEF,
eft ventricular ejection fraction; MLHF, Minnesota Living with Heart Failure
uestionnaire; SF-36, Short-Form 36; BUN, blood urea nitrogen; DBP,
iastolic blood pressure; SBP, systolic blood pressure; NYHA, New York
eart Association; ACE, angiotensin-converting enzyme; ARB, angiotensin
eceptor blocker. *P value is based on comparing log-transformed mean
alues. †Patients can have more than 1 cause.
The Journal of Thoracic aABLE E2. Mitral valve ring type
ing type
No. of
patients
Percentage
of 155
axter/Cosgrove/Edwards (Edwards
Lifesciences, Irvine, Calif)*
67 43.2
hysio-ring (Edwards Lifesciences) 31 20.0
uran (Medtronic, Minneapolis, Minn) 22 14.2
arbomedics (Austin, Tex) 16 10.3
arpentier-Edwards (Edwards
Lifesciences)
12 7.7
eguin (St Jude Medical, St Paul, Minn) 6 3.9
t Jude Tailor (St Jude Medical) 1 0.6
These include Baxter Physio rings, Cosgrove Edwards Annuloplasty rings,nd Cardiovascular Surgery ● Volume 132, Number 3 577.e4
